Vertical inhibition of p110α/ AKT and N‐cadherin enhances treatment efficacy in PIK3CA ‐aberrated ovarian cancer cells
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.13761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Shibo Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Class I Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Cadherins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Grants Council of Hong Kong, Innovative Research Team of High-Level Local Universities in Shanghai.
Abstract (Originalsprache)
Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [ PIK3CA , encoding PI3Kalpha (also known as p110α)] is one of the most commonly aberrated genes in human cancers. In serous ovarian cancer, PIK3CA amplification is highly frequent but PIK3CA point mutation is rare. However, whether PIK3CA amplification and PIK3CA driver mutations have the same functional impact in the disease is unclear. Here, we report that both PIK3CA amplification and E545K mutation are tumorigenic. While the protein kinase B (AKT) signaling axis was activated in both E545K knock‐in cells and PIK3CA ‐overexpressing cells, the mitogen‐activated protein kinase 3/1 (ERK1/2) pathway was induced selectively by E545K mutation but not PIK3CA amplification. Intriguingly, AKT signaling in these PIK3CA ‐aberrated cells increased transcriptional coactivator YAP1 (YAP) Ser127 phosphorylation and thereby cytoplasmic YAP levels, which in turn increased cell migration through Ras‐related C3 botulinum toxin substrate 1 (RAC1) activation. In addition to the altered YAP signaling, AKT upregulated N‐cadherin expression, which also contributed to cell migration. Pharmacological inhibition of N‐cadherin reduced cell migratory potential. Importantly, co‐targeting N‐cadherin and p110α/AKT caused additive reduction in cell migration in vitro and metastases formation in vivo . Together, this study reveals the molecular pathways driven by the PIK3CA aberrations and the exploitable vulnerabilities in PIK3CA ‐aberrated serous ovarian cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China.
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Gua…
- Division of Cancer Medicine, Department of Genomic Medicine, UT MD Anderson Cancer Centre, Houston, TX, USA.
- State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, China.
- Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China.
ORCID-Profile: Lydia W T Cheung
Förderung
- National Natural Science Foundation of China
- Research Grants Council of Hong Kong
- Innovative Research Team of High-Level Local Universities in Shanghai
- 111 Project
- Higher Education Discipline Innovation Project
Zitieren
APA
Zhang, S., Hong, H. I., Mak, V. C. Y., Zhou, Y., Lu, Y., Zhuang, G., & Cheung, L. W. T. (2025). Vertical inhibition of p110α/ AKT and N‐cadherin enhances treatment efficacy in PIK3CA ‐aberrated ovarian cancer cells. Molecular Oncology. https://doi.org/10.1002/1878-0261.13761
Vancouver
Zhang S, Hong HI, Mak VCY, Zhou Y, Lu Y, Zhuang G, et al. Vertical inhibition of p110α/ AKT and N‐cadherin enhances treatment efficacy in PIK3CA ‐aberrated ovarian cancer cells. Molecular Oncology. 2025. doi:10.1002/1878-0261.13761
BibTeX
@article{Zhang2025,
author = {Zhang, Shibo and Hong, Hei Ip and Mak, Victor C Y and Zhou, Yuan and Lu, Yiling and Zhuang, Guanglei and Cheung, Lydia W T},
title = {Vertical inhibition of p110α/ AKT and N‐cadherin enhances treatment efficacy in PIK3CA ‐aberrated ovarian cancer cells},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.13761}
}
EUVIMED